Tiew-Hwa Katherine Teng

Tiew-Hwa Katherine Teng

Auto-generated profile, based on publicly available information

Tiew-Hwa Katherine Teng

National Heart Centre Singapore, Singapore

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 August 2022 in Cardiac Failure Review
Verified
Journal Article
Open access
PDF file
KTKanako Teramoto
Kanako Teramoto
TTTiew-Hwa Katherine Teng
Tiew-Hwa Katherine Teng
CCChanchal Chandramouli
Chanchal Chandramouli
JTJasper Tromp
Jasper Tromp
YSYasuhiko Sakata
Yasuhiko Sakata
CLCarolyn Sp Lam
Carolyn Sp Lam
Heart failure (HF) with preserved ejection (HFpEF) constitutes a large and growing proportion of patients with HF around the world, and is now responsible for more than half of all HF cases in ageing societies. While classically described as a condition of elderly, hypertensive women, recent studies suggest heterogeneity in clinical phenotypes involving differential characteristics and pathophysiological mechanisms. Despite a paucity of disease-modifying therapy for HFpEF, an understanding of phenotypic similarities and differences among patients with HFpEF around the world provides the foundation to recognise the clinical condition for early treatment, as well as to identify modifiable risk factors for preventive intervention. This review summarises the epidemiology of HFpEF, its common clinical features and risk factors, as well as differences by age, comorbidities, race/ethnicity and geography.

7 May 2024 in Journal of the American Heart Association
Verified
Journal Article
Open access
PDF file
KTKanako Teramoto
Kanako Teramoto
WTWan Ting Tay
Wan Ting Tay
JTJasper Tromp
Jasper Tromp
WOWouter Ouwerkerk
Wouter Ouwerkerk
TTTiew‐Hwa Katherine Teng
Tiew‐Hwa Katherine Teng
CLCarolyn S. P. Lam
Carolyn S. P. Lam
Background: The relationship of serial NT‐proBNP (N‐terminal pro‐B‐type natriuretic peptide) measurements with changes in cardiac features and outcomes in heart failure (HF) remains incompletely understood. We determined whether common clinical covariates impact these relationships. Methods and Results: In 2 nationwide observational populations with HF, the relationship of serial NT‐proBNP measurements with serial echocardiographic parameters and outcomes was analyzed, further stratified by HF with reduced versus preserved left ventricular ejection fraction, inpatient versus outpatient enrollment, age, obesity, chronic kidney disease, atrial fibrillation, and attainment of ≥50% guideline‐recommended doses of renin‐angiotensin system inhibitors and β‐blockers. Among 1911 patients (mean±SD age, 65.1±13.4 years; 26.6% women; 62% inpatient and 38% outpatient), NT‐proBNP declined overall, with more rapid declines among inpatients, those with obesity, those with atrial fibrillation, and those attaining ≥50% guideline‐recommended doses. Each doubling of NT‐proBNP was associated with increases in left ventricular volume (by 6.1 mL), E/e′ (transmitral to mitral annular early diastolic velocity ratio) (by 1.4 points), left atrial volume (by 3.6 mL), and reduced left ventricular ejection fraction (by −2.1%). The effect sizes of these associations were lower among patients with HF with preserved ejection fraction, atrial fibrillation, or advanced age ( P interaction <0.001). A landmark analysis identified that an SD increase in NT‐proBNP over 6 months was associated with a 27% increase in the risk of the composite event of HF hospitalization or all‐cause death between 6 months and 2 years (adjusted hazard ratio, 1.27 [95% CI, 1.15–1.40]; P <0.001). Conclusions: The relationships between NT‐proBNP and structural/functional remodeling differed by age, presence of atrial fibrillation, and HF phenotypes. The association of increased NT‐proBNP with increased risk of adverse outcomes was consistent in all subgroups.

6 February 2025 in Nature Communications
Verified
Journal Article
Open access
PDF file
QRQing-Wen Ren
Qing-Wen Ren
TTTiew-Hwa Katherine Teng
Tiew-Hwa Katherine Teng
WOWouter Ouwerkerk
Wouter Ouwerkerk
YTYi-Kei Tse
Yi-Kei Tse
CTChristopher Tze Wei Tsang
Christopher Tze Wei Tsang
KYKai-Hang Yiu
Kai-Hang Yiu
Remnant cholesterol, identified by triglyceride-rich lipoprotein, is a significant causal risk factor for ischemic heart diseases. The association of triglyceride levels with all-cause and cause-specific outcomes in heart failure (HF) remains unexplored. Using a previously validated territory-wide clinical information registry, all eligible patients diagnosed with HF (N = 127124) from 2000 to 2020 were included. In this population-based cohort (mean age: 71.4 ± 12.2 years, 51.8% male), the association between triglyceride levels and risk of all-cause mortality and cardiovascular disease was a U-shapedḍ curve. High triglyceride levels (≥3.0 mmol/L) were associated with atherosclerotic cardiovascular disease admission or death; conversely, lower triglyceride levels (<1.2 mmol/L) were associated with higher risks of HF readmission or death. The risk of adjusted all-cause mortality reached a nadir between triglyceride levels of 1.2 mmol/L and 3.0 mmol/L. Results were externally validated in BIOSTAT-CHF. Our findings have important implications for defining the role of triglyceride levels in contributing to the diverse outcomes in patients with HF.

16 November 2021 in Journal of the American Heart Association
Verified
Journal Article
Open access
PDF file
WTWan Ting Tay
Wan Ting Tay
TTTiew‐Hwa Katherine Teng
Tiew‐Hwa Katherine Teng
OSOliver Simon
Oliver Simon
WOWouter Ouwerkerk
Wouter Ouwerkerk
JTJasper Tromp
Jasper Tromp
TIthe ASIAN‐HF Investigators
the ASIAN‐HF Investigators
Background: Data on rehospitalizations for heart failure (HF) in Asia are scarce. We sought to determine the burden and predictors of HF (first and recurrent) rehospitalizations and all‐cause mortality in patients with HF and preserved versus reduced ejection fraction (preserved EF, ≥50%; reduced EF, <40%), in the multinational ASIAN‐HF (Asian Sudden Cardiac Death in Heart Failure) registry. Methods and Results: Patients with symptomatic (stage C) chronic HF were followed up for death and recurrent HF hospitalizations for 1 year. Predictors of HF hospitalizations or all‐cause mortality were examined with Cox regression for time to first event and other methods for recurrent events analyses. Among 1666 patients with HF with preserved EF (mean age, 68±12 years; 50% women), and 4479 with HF with reduced EF (mean age, 61±13 years; 22% women), there were 642 and 2302 readmissions, with 28% and 45% attributed to HF, respectively. The 1‐year composite event rate for first HF hospitalization or all‐cause death was 11% and 21%, and for total HF hospitalization and all‐cause death was 17.7 and 38.7 per 100 patient‐years in HF with preserved EF and HF with reduced EF, respectively. In HF with preserved EF, consistent independent predictors of these clinical end points included enrollment as an inpatient, Southeast Asian location, and comorbid chronic kidney disease or atrial fibrillation. The same variables were predictive of outcomes in HF with reduced EF except atrial fibrillation, and also included Northeast Asian location, older age, elevated heart rate, decreased systolic blood pressure, diabetes, smoking, and non‐usage of beta blockers. Conclusions: One‐year HF rehospitalization and mortality rates were high among Asian patients with HF. Predictors of outcomes identified in this study could aid in risk stratification and timely interventions. Registration: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT01633398.

9 August 2024 in European Journal of Heart Failure
Verified
Journal Article
Open access
TCThong Huy Cao
Thong Huy Cao
WTWan Ting Tay
Wan Ting Tay
DJDonald J.L. Jones
Donald J.L. Jones
JCJohn George Franklin Cleland
John George Franklin Cleland
JTJasper Tromp
Jasper Tromp
LNLeong L. Ng
Leong L. Ng
Aims: We investigated the prevalence, clinical characteristics, and prognosis of patients with heart failure (HF) with improved ejection fraction (HFimpEF). Methods and results: We used data from BIOSTAT‐CHF including patients with a left ventricular ejection fraction (LVEF) ≤40% at baseline who had LVEF re‐assessed at 9 months. HFimpEF was defined as a LVEF >40% and a LVEF ≥10% increase from baseline at 9 months. We validated findings in the ASIAN‐HF registry. The primary outcome was a composite of time to HF rehospitalization or all‐cause mortality. In BIOSTAT‐CHF, about 20% of patients developed HFimpEF, that was associated with a lower primary event rate of all‐cause mortality (hazard ratio [HR] 0.52, 95% confidence interval [CI] 0.28–0.97, p = 0.040) and the composite endpoint (HR 0.46, 95% CI 0.30–0.70, p < 0.001) compared with patients who remained in persistent HF with reduced ejection fraction (HFrEF). The findings were similar in the ASIAN‐HF (HR 0.40, 95% CI 0.18–0.89, p = 0.024, and HR 0.29, 95% CI 0.17–0.48, p < 0.001). Five independently common predictors for HFimpEF in both BIOSTAT‐CHF and ASIAN‐HF were female sex, absence of ischaemic heart disease, higher LVEF, smaller left ventricular end‐diastolic and end‐systolic diameter at baseline. A predictive model combining only five predictors (absence of ischaemic heart disease and left bundle branch block, smaller left ventricular end‐systolic and left atrial diameter, and higher platelet count) for HFimpEF in the BIOSTAT‐CHF achieved an area under the curve of 0.772 and 0.688 in the ASIAN‐HF (due to missing left atrial diameter and platelet count). Conclusions: Approximately 20–30% of patients with HFrEF improved to HFimpEF within 1 year with better clinical outcomes. In addition, the predictive model with clinical predictors could more accurately predict HFimpEF in patients with HFrEF.

23 May 2022 in ESC Heart Failure
Verified
Journal Article
Open access
CDCecilia Danielson
Cecilia Danielson
GLGabriele Lileikyte
Gabriele Lileikyte
WOWouter Ouwerkerk
Wouter Ouwerkerk
CLCarolyn S.P. Lam
Carolyn S.P. Lam
DEDavid Erlinge
David Erlinge
TTTiew-Hwa Katherine Teng
Tiew-Hwa Katherine Teng
Aims: Recent studies have suggested potential sex differences in treatment response to pharmacological therapies in heart failure (HF). We performed a systematic review and meta-analysis of studies comparing treatment effects between men and women with HF and reduced ejection fraction (HFrEF) using established guideline-directed medical therapy and other emerging pharmacological treatments. Methods and results: Systematic search was performed on PubMed, Embase, and Cochrane Library for randomized controlled trials published in 1990–2021. Outcomes were all-cause mortality and combined outcome of all-cause mortality and/or hospitalization for HF. Of 618 articles identified, 25 articles and 100 213 patients (mean age 62 ± 1.7 years, women 23.1%, mean left ventricular ejection fraction 26.6 ± 1.3%) were included in the systematic review and meta-analysis. For the outcome of all-cause mortality, there was no evidence of treatment heterogeneity by sex for renin-angiotensin system inhibitors (RASi) [hazard ratio (HR) 0.86 (95% confidence interval 0.75–0.99) in men; HR 0.97 (0.77–1.23) in women; Pinteraction = 0.288], or for beta-blockers (BB) [HR 0.71 (0.59–0.86) in men; HR 0.87 (0.73–1.03) in women; Pinteraction = 0.345]. Similarly, for the composite outcome of death or HF hospitalization, there was no evidence of treatment heterogeneity by sex for RASi [HR 0.84 (0.77–0.93) in men; HR 0.94 (0.81–1.08) in women; Pinteraction = 0.210] or BB [HR 0.76 (0.64–0.90) in men; HR 0.72 (0.60–0.86) in women; Pinteraction = 0.650]. Results for mineralocorticoid receptor antagonists (MRA) and sodium-glucose cotransporter-2 inhibitors (SGLT2i) from previously published meta-analyses were included in the review. For the combined outcome of cardiovascular death or HF hospitalization, no significant interaction for sex was observed for MRA (Pinteraction = 0.78) or SGLT2i (Pinteraction = 0.37). Results for emerging pharmacological treatments, such as soluble guanylate cyclase stimulators and cardiac myosin activators, were included in the review and showed consistent treatment effects between men and women. Conclusions: Our meta-analysis showed no differences between sex in treatment effect for BB and RASi. Review on previously published trials for MRA, SGLT2i, and emerging therapies presented consistent treatment effects between men and women.